tradingkey.logo
tradingkey.logo
Buscar

PAVmed Inc

PAVM
Añadir a la lista de seguimiento
5.710USD
-0.540-8.57%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
35.80MCap. mercado
PérdidaP/E TTM

Más Datos de PAVmed Inc Compañía

PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates in the medical devices, diagnostics, and digital health sectors. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is a digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices.

Información de PAVmed Inc

Símbolo de cotizaciónPAVM
Nombre de la empresaPAVmed Inc
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoAklog (Lishan)
Número de empleados39
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 27
Dirección360 Madison Avenue
CiudadNEW YORK
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal10017
Teléfono12129494319
Sitio Webhttps://pavmed.com/
Símbolo de cotizaciónPAVM
Fecha de salida a bolsaJul 27, 2016
Director ejecutivoAklog (Lishan)

Ejecutivos de PAVmed Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
357.62K
+97.87%
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
21.65K
+64.33%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
21.10K
+66.03%
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
19.34K
+72.04%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--
Mr. Timothy (Tim) Baxter
Mr. Timothy (Tim) Baxter
Independent Director
Independent Director
--
--
Mr. Shaun M. O'Neil
Mr. Shaun M. O'Neil
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
--
Mr. Michael A. Gordon
Mr. Michael A. Gordon
General Counsel, Secretary
General Counsel, Secretary
--
--
Mr. Matt Riley
Mr. Matt Riley
Director of Investor Relations
Director of Investor Relations
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Lishan Aklog, M.D.
Dr. Lishan Aklog, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
357.62K
+97.87%
Mr. Michael J. Glennon
Mr. Michael J. Glennon
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
21.65K
+64.33%
Mr. Ronald M. (Ron) Sparks
Mr. Ronald M. (Ron) Sparks
Independent Director
Independent Director
21.10K
+66.03%
Mr. Sundeep Agrawal, M.D.
Mr. Sundeep Agrawal, M.D.
Director
Director
19.34K
+72.04%
Mr. Dennis M. Mcgrath
Mr. Dennis M. Mcgrath
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Ms. Debra J. White
Ms. Debra J. White
Independent Director
Independent Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de PAVmed Inc?

Los cinco principales accionistas de PAVmed Inc son: Dr. Lishan Aklog, M.D.

¿Cuántas instituciones poseen acciones de PAVmed Inc (PAVM)?

A fecha de 2026Q1, 61 instituciones poseen acciones de PAVmed Inc, con un valor de mercado combinado de aproximadamente 736.95K, lo que representa el 10.13% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 659921.00.